Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Hepcortespenlisimut-L (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Immunitor
- 10 Jun 2017 Biomarkers information updated
- 14 Mar 2017 Planned number of patients changed from 100 to 120.
- 14 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.